Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors
E Boscaro, I Urbino, FM Catania, G Arrigo, C Secreto… - Cancers, 2023 - mdpi.com
Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Y Tan, L Xin, Q Wang, R Xu, X Tong, G Chen, L Ma… - Cancer letters, 2024 - Elsevier
Acute myeloid leukemia (AML) patients carrying Fms-like tyrosine kinase 3-internal tandem
duplication (FLT3-ITD) mutations often face a poor prognosis. While some FLT3 inhibitors …
duplication (FLT3-ITD) mutations often face a poor prognosis. While some FLT3 inhibitors …
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations
Acute myeloid leukemia (AML) with CEBPA bZIP in-frame mutations (CEBPA bZIP-inf) is
classified within the favorable-risk group by the 2022 European LeukemiaNet (ELN-2022) …
classified within the favorable-risk group by the 2022 European LeukemiaNet (ELN-2022) …
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
M Tecik, A Adan - Current Treatment Options in Oncology, 2024 - Springer
Current Treatment Options in Oncology and how they modulate FLT3I's activity is important
to rationalize combinational treatment approaches including FLT3Is and modulators of …
to rationalize combinational treatment approaches including FLT3Is and modulators of …
Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients
YH Wang, AM Orgueira, CC Lin, CY Yao, MY Lo… - Scientific Reports, 2024 - nature.com
Abstract The European Leukemia Net recommendations provide valuable guidance in
treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic …
treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic …
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
GY Song, HJ Kim, TH Kim, SY Ahn, SH Jung, M Kim… - Scientific Reports, 2024 - nature.com
This study aimed to validate the 2022 European LeukemiaNet (ELN) risk stratification for
acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to …
acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to …
Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in …
Y Cao, C Zhang, X Zhao, J Huang, Z Zhang… - Bone Marrow …, 2023 - nature.com
NUP98:: RARG)[1]. Allo-HSCT might be the important curative therapy for intermediate-to
adverse-risk AML [2], however, its efficacy and safety were still unclear in AML patients with …
adverse-risk AML [2], however, its efficacy and safety were still unclear in AML patients with …
Identifying prognostic gene panels in acute myeloid leukemia
J Sanchez-Garcia, J Serrano… - Expert Review of …, 2023 - Taylor & Francis
Introduction Acute myeloid leukemia (AML) is a heterogeneous disease currently including
12 entities defined by genetic findings with remarkable differences in prognosis and targeted …
12 entities defined by genetic findings with remarkable differences in prognosis and targeted …
FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia—Even in the Era of New Treatment Modalities Still a Significant Player
S Anžej Doma, M Sever, G Jakoš… - Journal of Clinical …, 2024 - mdpi.com
(1) Background: Relapsed/refractory (r/r) and secondary acute myeloid leukemia are
highlighted by chemoresistance and poor outcomes. The aim of the study was to assess the …
highlighted by chemoresistance and poor outcomes. The aim of the study was to assess the …
Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China
E Chen, C Jiao, J Yu, Y Gong, D Jin, X Ma… - Cancer …, 2023 - Wiley Online Library
Abstract Background The European LeukemiaNet (ELN) risk classification system for acute
myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk …
myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk …